Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study

J Diabetes. 2020 Jan;12(1):91-94. doi: 10.1111/1753-0407.12989. Epub 2019 Oct 23.

Authors

Stanley H Hsia¹, Petra Duran¹, Martin L Lee¹, Mayer B Davidson¹

Affiliation

¹ Division of Endocrinology, Metabolism & Molecular Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, California.

PMID: 31574564
DOI: 10.1111/1753-0407.12989

No abstract available

Keywords: anti-inflammation; hydroxychloroquine; insulin sensitivity; pioglitazone.

Publication types

Comparative Study
Letter
Randomized Controlled Trial

MeSH terms

Adult
Aged
Antimalarials / therapeutic use
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / drug therapy*
Drug Therapy, Combination
Female
Glycated Hemoglobin / analysis
Humans
Hydroxychloroquine / therapeutic use*
Hypoglycemic Agents / therapeutic use
Male
Metformin / therapeutic use*
Middle Aged
Outcome Assessment, Health Care / methods
Outcome Assessment, Health Care / statistics & numerical data
Pilot Projects
Pioglitazone / therapeutic use*
Prospective Studies
Sulfonylurea Compounds / therapeutic use*
Treatment Failure

Substances

Antimalarials
Glycated Hemoglobin A
Hypoglycemic Agents
Sulfonylurea Compounds
Hydroxychloroquine
Metformin
Pioglitazone

Grants and funding